Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

BACKGROUND: Raltegravir 1200mg (2×600mg tablets) once daily (QD) demonstrated noninferior efficacy and similar safety to raltegravir 400mg twice daily (BID) at week 48 of the ONCEMRK trial. Here, we report the week 96 results from this study. METHODS: ONCEMRK is a phase 3, multicenter, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cahn, Pedro, Sax, Paul E., Squires, Kathleen, Molina, Jean-Michel, Ratanasuwan, Winai, Rassool, Mohammed, Bloch, Mark, Xu, Xia, Zhou, Yan, Homony, Brenda, Hepler, Deborah, Teppler, Hedy, Hanna, George J., Nguyen, Bach-Yen, Greaves, Wayne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075877/
https://www.ncbi.nlm.nih.gov/pubmed/29771789
http://dx.doi.org/10.1097/QAI.0000000000001723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075877/
https://www.ncbi.nlm.nih.gov/pubmed/29771789
http://dx.doi.org/10.1097/QAI.0000000000001723

Ejemplares similares